To receive a free copy of this video click here
Through the use of 3D animation, clinical images, and expert commentary from a leading vitreoretinal specialist Mark S. Hughes, MD*, this video provides a comprehensive review of the progression of wet AMD, from angiogenesis to vessel stabilization. The video demonstrates that as vessels mature into established abnormal vessels they become less dependent on VEGF.
Visudyne® (verteporfin for injection) targets established abnormal vessels to help protect against vision loss due to wet AMD.
*Mark S. Hughes, MD, is a consultant to Novartis Pharmaceuticals
Corporation. Dr. Hughes is a vitreoretinal specialist at the Ophthalmic
Consultants of Boston and is affiliated with the Schepens Eye Research
Institute of the Harvard Medical School.
Indication
Visudyne® is indicated for the treatment of predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
Important Safety Information
Visudyne is contraindicated for patients with porphyria or known hypersensitivity to any component of Visudyne.
Infusion-related transient back pain occurred with Visudyne only. Verteporfin infusion induces temporary photosensitivity; patients should avoid exposure of skin and eyes to direct sunlight or bright indoor light for 5 days. To prevent extravasation, avoid fragile hand veins in favor of larger antecubital veins.
Severe vision decrease (≥4 lines) was reported within 7 days in 1% to 5% of patients. Partial recovery occurs in some patients. Do not re-treat these patients until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully weighed.
The most frequently reported adverse events (10%-30% incidence) were injection site reactions (including extravasation and rashes), blurred vision, decreased visual acuity, and visual field defects.
Please click here for full Prescribing Information
VSD-900160